Immunooncology: Genmab teams up with Immatics

According to the research collaboration and exclusive license agreement, the companies will conduct joint research to combine Immatics’ XPRESIDENT® and Bispecific TCR technology platforms with Genmab’s proprietary antibody technologies. Genmab will receive an exclusive license to three proprietary targets from Immatics, with an option to license up to two additional targets at predetermined economics.

Copenhagen-based Genmab will pay Immatics an upfront fee of US$54m. The German biotech is also eligible to receive up to US$550m in development, regulatory and commercial milestone payments for each product, as well as tiered royalties on net sales.

Our bispecific TCR technology exhibits exceptional potency and favourable pharmacokinetic properties by combining Immatics’ proprietary T-cell engaging format with our high-affinity and highly specific T-cell receptors, said Carsten Reinhardt, Chief Medical Officer and Managing Director of Immatics.

This collaboration with Immatics gives us the opportunity to combine our unique technologies and expertise to create differentiated novel next-generation therapies, added Genmab CEO Jan van de Winkel.